APO Research
Talk to an analyst

APO RESEARCH · REPORT

Celecoxib

Celecoxib capsules (patent brand name: CELEBREX), is a new generation of non-steroidal anti-inflammatory and analgesic drugs, mainly through the selective inhibition of coX-2 (COX-2) to inhibit the production of prostaglandins, achieve anti-inflammatory and analgesic effects.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Celecoxib capsules (patent brand name: CELEBREX), is a new generation of non-steroidal anti-inflammatory and analgesic drugs, mainly through the selective inhibition of coX-2 (COX-2) to inhibit the production of prostaglandins, achieve anti-inflammatory and analgesic effects.

The drug is used to relieve symptoms and signs of osteoarthritis and rheumatoid arthritis in adults and has fewer gastrointestinal side effects than traditional non-steroidal anti-inflammatory drugs.

Selected research

Market Outlook & Growth Opportunities

Global Celecoxib Market Outlook and Growth Opportunities 2026

30 December 2025194 pages

Choose your research edition.

Industry ResearchCelecoxib Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Celecoxib Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Celecoxib Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Celecoxib Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Celecoxib Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

Celecoxib capsules (patent brand name: CELEBREX), is a new generation of non-steroidal anti-inflammatory and analgesic drugs, mainly through the selective inhibition of coX-2 (COX-2) to inhibit the production of prostaglandins, achieve anti-inflammatory and analgesic effects.

The drug is used to relieve symptoms and signs of osteoarthritis and rheumatoid arthritis in adults and has fewer gastrointestinal side effects than traditional non-steroidal anti-inflammatory drugs.

Data show that more than 400 million people worldwide are currently affected by joint diseases.

Read the full market overview

The prevalence of osteoarthritis is 17 percent among people aged 40, 62 percent among people over 60 and 80 percent among people over 75.

The number of patients with arthritis in mainland China is more than 10% of the total population, well over 100 million, and the incidence of arthritis increases with age, and the number of patients is still increasing.

At present, the burden of chronic diseases will increase by 40% due to the aging of the population.

As the population ages, anti-inflammatory and anti-rheumatic drugs will enter a phase of rapid growth.

Globally, whether prescription drugs or non-prescription drugs, Xibu is widely used in clinical practice.

At present, the best seller in the international market is Celixib. Celixib market will continue to grow steadily in the next few years.

At present, the global Celecoxib market is basically occupied by Pfizer, which has formed an oligopoly.

It accounted for 63.39% of the global market in 2019.

As of 2019, China relies entirely on Pfizer for celecoxib imports.

Since 2020, some domestic drug companies have been gradually approved by FDA and CFDA. The introduction of celecoxib generic drugs by local companies will break the monopoly of import.

This report provides an overview of the global Celecoxib market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Celecoxib and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Celecoxib sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Celecoxib market size, projected growth trends, production technologies, key applications, and end-use industries.

Celecoxib Segment by Company

Pfizer Inc

Teva

Mylan

Apotex

Lupin

Hengrui Medicine

Celecoxib Segment by Type

50mg

100mg

200mg

400mg

Celecoxib Segment by Application

Rheumatoid arthritis

osteoarthritis

Acute pain

Musculoskeletal pain

Other diseases

Celecoxib Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Celecoxib status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Celecoxib market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Celecoxib significant trends, drivers, influence factors in global and regions.

6. To analyze Celecoxib competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Celecoxib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Celecoxib and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Celecoxib.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Celecoxib market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Celecoxib industry.

Chapter 3: Detailed analysis of Celecoxib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Celecoxib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Celecoxib in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Celecoxib Industry Trends Table 2. Celecoxib Industry Drivers Table 3. Celecoxib Industry Opportunities and Challenges Table 4. Celecoxib Industry Restraints Table 5. Global Celecoxib Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Celecoxib Revenue Share by Company (2021-2026) Table 7. Global Celecoxib Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Celecoxib Sales Volume Share by Company (2021-2026) Table 9. Global Celecoxib Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Celecoxib Company Ranking, (2024-2026) & (USD Million) Table 11. Global Celecoxib Key Company Manufacturing Base & Headquarters Table 12. Global Celecoxib Company, Product Type & Application Table 13. Global Celecoxib Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Celecoxib by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 50mg Table 18. Significant Companies of 100mg Table 19. Significant Companies of 200mg Table 20. Significant Companies of 400mg Table 21. Global Celecoxib Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Celecoxib Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Celecoxib Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Celecoxib Sales Volume Share by Type (2021-2026) Table 25. Global Celecoxib Sales Volume Share by Type (2027-2032) Table 26. Global Celecoxib Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Celecoxib Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Celecoxib Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Celecoxib Sales Value Share by Type (2021-2026) Table 30. Global Celecoxib Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Rheumatoid arthritis Table 32. Significant Companies of osteoarthritis Table 33. Significant Companies of Acute pain Table 34. Significant Companies of Musculoskeletal pain Table 35. Significant Companies of Other diseases Table 36. Global Celecoxib Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Celecoxib Sales Volume by Application (2021-2026) & (K Units) Table 38. Global Celecoxib Sales Volume by Application (2027-2032) & (K Units) Table 39. Global Celecoxib Sales Volume Share by Application (2021-2026) Table 40. Global Celecoxib Sales Volume Share by Application (2027-2032) Table 41. Global Celecoxib Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Celecoxib Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Celecoxib Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Celecoxib Sales Value Share by Application (2021-2026) Table 45. Global Celecoxib Sales Value Share by Application (2027-2032) Table 46. Global Celecoxib Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Celecoxib Sales by Region (2021-2026) & (K Units) Table 48. Global Celecoxib Sales Market Share by Region (2021-2026) Table 49. Global Celecoxib Sales by Region (2027-2032) & (K Units) Table 50. Global Celecoxib Sales Market Share by Region (2027-2032) Table 51. Global Celecoxib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Celecoxib Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Celecoxib Sales Value Share by Region (2021-2026) Table 54. Global Celecoxib Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Celecoxib Sales Value Share by Region (2027-2032) Table 56. Global Celecoxib Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Celecoxib Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Celecoxib Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Global Celecoxib Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Celecoxib Sales by Country (2021-2026) & (K Units) Table 61. Global Celecoxib Sales Market Share by Country (2021-2026) Table 62. Global Celecoxib Sales by Country (2027-2032) & (K Units) Table 63. Global Celecoxib Sales Market Share by Country (2027-2032) Table 64. Global Celecoxib Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Celecoxib Sales Value Market Share by Country (2021-2026) Table 66. Global Celecoxib Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Celecoxib Sales Value Market Share by Country (2027-2032) Table 68. Pfizer Inc Company Information Table 69. Pfizer Inc Business Overview Table 70. Pfizer Inc Celecoxib Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Pfizer Inc Celecoxib Product Portfolio Table 72. Pfizer Inc Recent Development Table 73. Teva Company Information Table 74. Teva Business Overview Table 75. Teva Celecoxib Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Teva Celecoxib Product Portfolio Table 77. Teva Recent Development Table 78. Mylan Company Information Table 79. Mylan Business Overview Table 80. Mylan Celecoxib Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Mylan Celecoxib Product Portfolio Table 82. Mylan Recent Development Table 83. Apotex Company Information Table 84. Apotex Business Overview Table 85. Apotex Celecoxib Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Apotex Celecoxib Product Portfolio Table 87. Apotex Recent Development Table 88. Lupin Company Information Table 89. Lupin Business Overview Table 90. Lupin Celecoxib Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Lupin Celecoxib Product Portfolio Table 92. Lupin Recent Development Table 93. Hengrui Medicine Company Information Table 94. Hengrui Medicine Business Overview Table 95. Hengrui Medicine Celecoxib Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Hengrui Medicine Celecoxib Product Portfolio Table 97. Hengrui Medicine Recent Development Table 98. Key Raw Materials Table 99. Raw Materials Key Suppliers Table 100. Celecoxib Distributors List Table 101. Celecoxib Customers List Table 102. Research Programs/Design for This Report Table 103. Authors List of This Report Table 104. Secondary Sources Table 105. Primary Sources List of Figures Figure 1. Celecoxib Product Image Figure 2. Global Celecoxib Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Celecoxib Sales Value (2021-2032) & (US$ Million) Figure 4. Global Celecoxib Sales (2021-2032) & (K Units) Figure 5. Global Celecoxib Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Celecoxib Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 50mg Image Figure 10. 100mg Image Figure 11. 200mg Image Figure 12. 400mg Image Figure 13. Global Celecoxib Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Celecoxib Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Celecoxib Sales Volume Share by Type (2021-2032) Figure 16. Global Celecoxib Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Celecoxib Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Celecoxib Sales Value Share by Type (2021-2032) Figure 19. Rheumatoid arthritis Image Figure 20. osteoarthritis Image Figure 21. Acute pain Image Figure 22. Musculoskeletal pain Image Figure 23. Other diseases Image Figure 24. Global Celecoxib Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Celecoxib Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Celecoxib Sales Volume Share by Application (2021-2032) Figure 27. Global Celecoxib Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Celecoxib Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Celecoxib Sales Value Share by Application (2021-2032) Figure 30. Global Celecoxib Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 31. Global Celecoxib Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Celecoxib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Celecoxib Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Celecoxib Sales Value (2021-2032) & (US$ Million) Figure 35. North America Celecoxib Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Celecoxib Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Celecoxib Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Celecoxib Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Celecoxib Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Celecoxib Sales Value (2021-2032) & (US$ Million) Figure 41. South America Celecoxib Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Celecoxib Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Celecoxib Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Celecoxib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Celecoxib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Celecoxib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Celecoxib Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Celecoxib Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • 50mg
  • 100mg
  • 200mg
  • 400mg
Applications
  • Rheumatoid arthritis
  • osteoarthritis
  • Acute pain
  • Musculoskeletal pain
  • Other diseases
Companies covered
  • Pfizer Inc
  • Teva
  • Mylan
  • Apotex
  • Lupin
  • Hengrui Medicine

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Celecoxib Sales Value (2021-2032)
  4. 1.2.2 Global Celecoxib Sales Volume (2021-2032)
  5. 1.2.3 Global Celecoxib Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Celecoxib Market Dynamics
  1. 2.1 Celecoxib Industry Trends
  2. 2.2 Celecoxib Industry Drivers
  3. 2.3 Celecoxib Industry Opportunities and Challenges
  4. 2.4 Celecoxib Industry Restraints
3 Celecoxib Market by Company
  1. 3.1 Global Celecoxib Company Revenue Ranking in 2025
  2. 3.2 Global Celecoxib Revenue by Company (2021-2026)
  3. 3.3 Global Celecoxib Sales Volume by Company (2021-2026)
  4. 3.4 Global Celecoxib Average Price by Company (2021-2026)
  5. 3.5 Global Celecoxib Company Ranking (2024-2026)
  6. 3.6 Global Celecoxib Company Manufacturing Base and Headquarters
  7. 3.7 Global Celecoxib Company Product Type and Application
  8. 3.8 Global Celecoxib Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Celecoxib Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Celecoxib Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Celecoxib Market by Type
  1. 4.1 Celecoxib Type Introduction
  2. 4.1.1 50mg
  3. 4.1.2 100mg
  4. 4.1.3 200mg
  5. 4.1.4 400mg
  6. 4.2 Global Celecoxib Sales Volume by Type
  7. 4.2.1 Global Celecoxib Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Celecoxib Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Celecoxib Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Celecoxib Sales Value by Type
  11. 4.3.1 Global Celecoxib Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Celecoxib Sales Value by Type (2021-2032)
  13. 4.3.3 Global Celecoxib Sales Value Share by Type (2021-2032)
5 Celecoxib Market by Application
  1. 5.1 Celecoxib Application Introduction
  2. 5.1.1 Rheumatoid arthritis
  3. 5.1.2 osteoarthritis
  4. 5.1.3 Acute pain
  5. 5.1.4 Musculoskeletal pain
  6. 5.1.5 Other diseases
  7. 5.2 Global Celecoxib Sales Volume by Application
  8. 5.2.1 Global Celecoxib Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Celecoxib Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Celecoxib Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Celecoxib Sales Value by Application
  12. 5.3.1 Global Celecoxib Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Celecoxib Sales Value by Application (2021-2032)
  14. 5.3.3 Global Celecoxib Sales Value Share by Application (2021-2032)
6 Celecoxib Regional Sales and Value Analysis
  1. 6.1 Global Celecoxib Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Celecoxib Sales by Region (2021-2032)
  3. 6.2.1 Global Celecoxib Sales by Region: 2021-2026
  4. 6.2.2 Global Celecoxib Sales by Region (2027-2032)
  5. 6.3 Global Celecoxib Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Celecoxib Sales Value by Region (2021-2032)
  7. 6.4.1 Global Celecoxib Sales Value by Region: 2021-2026
  8. 6.4.2 Global Celecoxib Sales Value by Region (2027-2032)
  9. 6.5 Global Celecoxib Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Celecoxib Sales Value (2021-2032)
  12. 6.6.2 North America Celecoxib Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Celecoxib Sales Value (2021-2032)
  15. 6.7.2 Europe Celecoxib Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Celecoxib Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Celecoxib Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Celecoxib Sales Value (2021-2032)
  21. 6.9.2 South America Celecoxib Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Celecoxib Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Celecoxib Sales Value Share by Country, 2025 VS 2032
7 Celecoxib Country-level Sales and Value Analysis
  1. 7.1 Global Celecoxib Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Celecoxib Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Celecoxib Sales by Country (2021-2032)
  4. 7.3.1 Global Celecoxib Sales by Country (2021-2026)
  5. 7.3.2 Global Celecoxib Sales by Country (2027-2032)
  6. 7.4 Global Celecoxib Sales Value by Country (2021-2032)
  7. 7.4.1 Global Celecoxib Sales Value by Country (2021-2026)
  8. 7.4.2 Global Celecoxib Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Celecoxib Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Celecoxib Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Celecoxib Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Celecoxib Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Celecoxib Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Celecoxib Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Celecoxib Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Celecoxib Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Celecoxib Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Celecoxib Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Celecoxib Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Celecoxib Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Celecoxib Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Celecoxib Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Celecoxib Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Celecoxib Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Celecoxib Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Celecoxib Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Celecoxib Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Celecoxib Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Celecoxib Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Celecoxib Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Celecoxib Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Celecoxib Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Celecoxib Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Celecoxib Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Celecoxib Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Celecoxib Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Celecoxib Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Celecoxib Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Celecoxib Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Celecoxib Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Celecoxib Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Celecoxib Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Celecoxib Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Celecoxib Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Celecoxib Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Celecoxib Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Celecoxib Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Celecoxib Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Celecoxib Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Celecoxib Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Celecoxib Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Celecoxib Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Celecoxib Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Celecoxib Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Celecoxib Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Celecoxib Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Celecoxib Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Celecoxib Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Celecoxib Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Celecoxib Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Celecoxib Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Celecoxib Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Celecoxib Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Celecoxib Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Celecoxib Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Celecoxib Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Celecoxib Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Celecoxib Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Celecoxib Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Celecoxib Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Celecoxib Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Celecoxib Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Celecoxib Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Celecoxib Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Celecoxib Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Celecoxib Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Celecoxib Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Celecoxib Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Celecoxib Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Celecoxib Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Celecoxib Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Celecoxib Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Celecoxib Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Celecoxib Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Celecoxib Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Celecoxib Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Celecoxib Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Celecoxib Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Celecoxib Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Celecoxib Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Celecoxib Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Celecoxib Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer Inc
  2. 8.1.1 Pfizer Inc Company Information
  3. 8.1.2 Pfizer Inc Business Overview
  4. 8.1.3 Pfizer Inc Celecoxib Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Inc Celecoxib Product Portfolio
  6. 8.1.5 Pfizer Inc Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Celecoxib Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Teva Celecoxib Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Mylan
  14. 8.3.1 Mylan Company Information
  15. 8.3.2 Mylan Business Overview
  16. 8.3.3 Mylan Celecoxib Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Mylan Celecoxib Product Portfolio
  18. 8.3.5 Mylan Recent Developments
  19. 8.4 Apotex
  20. 8.4.1 Apotex Company Information
  21. 8.4.2 Apotex Business Overview
  22. 8.4.3 Apotex Celecoxib Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Apotex Celecoxib Product Portfolio
  24. 8.4.5 Apotex Recent Developments
  25. 8.5 Lupin
  26. 8.5.1 Lupin Company Information
  27. 8.5.2 Lupin Business Overview
  28. 8.5.3 Lupin Celecoxib Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Lupin Celecoxib Product Portfolio
  30. 8.5.5 Lupin Recent Developments
  31. 8.6 Hengrui Medicine
  32. 8.6.1 Hengrui Medicine Company Information
  33. 8.6.2 Hengrui Medicine Business Overview
  34. 8.6.3 Hengrui Medicine Celecoxib Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Hengrui Medicine Celecoxib Product Portfolio
  36. 8.6.5 Hengrui Medicine Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Celecoxib Value Chain Analysis
  2. 9.1.1 Celecoxib Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Celecoxib Sales Mode & Process
  6. 9.2 Celecoxib Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Celecoxib Distributors
  9. 9.2.3 Celecoxib Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst